ClinicalTrials.gg
CompletedNCT01091428Updated Jun 4, 2018Results posted

Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

A Phase 2 interventional study of Alisertib and Paclitaxel in Ovarian Carcinoma, Fallopian Tube Cancer and Peritoneal Cancer, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 4 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-04.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
191
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 155 studies testing paclitaxel in Ovarian Neoplasms — 13 open to participants now, 21 under way, 6 of them phase 3. Paclitaxel · Ovarian Neoplasms.

Enrollment
24th of 143
191 · median 50
Started
2010
with 10 others
Phase 2
83 of 155
8 open now
Registered
85th of 155
by date

Among the 155 studies testing paclitaxel in Ovarian Neoplasms, this one is the 24th largest by enrollment of the 143 interventional ones that give a count, is one of 11 that started in 2010, is one of 83 in phase 2, and was the 85th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

13 of the 155 studies testing paclitaxel in Ovarian Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies testing paclitaxel in Ovarian Neoplasms, or all of them as a file.
02

Study summary

This is an open-label, multicenter study with a nonrandomized Phase 1 portion and an open-label, randomized, Phase 2 portion evaluating MLN8237 in combination with weekly paclitaxel in adult female participants with advanced breast cancer (Phase 1 portion only) and recurrent ovarian cancer (both Phase 1 and Phase 2 portions).

Read the detailed description

The drug tested in this study was called alisertib. Alisertib was tested to treat people who have ovarian and breast cancer. This study looked at safety, any anti-tumor effect, and it also determined a recommended dose of alisertib plus paclitaxel to take into further studies. Pharmacokinetic blood samples were studied to characterize any effects on the concentration of each of the drugs when administered together.

The study enrolled 191 patients. Participants with Breast Cancer and Ovarian Cancer received one of the following escalating doses of alisertib in combination with paclitaxel in the Phase 1 lead-in portion of the study:

  • Alisertib 10 mg BID + Paclitaxel 80 mg/m\^2
  • Alisertib 20 mg BID + Paclitaxel 80 mg/m\^2
  • Alisertib 20 mg BID + Paclitaxel 60 mg/m\^2
  • Alisertib 30 mg BID + Paclitaxel 60 mg/m\^2
  • Alisertib 40 mg BID + Paclitaxel 60 mg/m\^2
  • Alisertib 50 mg BID + Paclitaxel 60 mg/m\^2

Once the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) was determined, participants were randomized to receive the following treatments in the Phase 2 portion of the study:

  • Alisertib 40 mg BID + Paclitaxel 60 mg/m\^2
  • Paclitaxel 80 mg/m\^2

This multi-center trial was conducted in the United States, Poland and France. The overall time to participate in this study was approximately 5 years. Participants made multiple visits to the clinic, and who did not experience disease progression (PD) were followed off-treatment once every 8 weeks until the occurrence of 110 progression-free survival (PFS) events.

03

Conditions studied

  • Ovarian Carcinoma
  • Fallopian Tube Cancer
  • Peritoneal Cancer
  • Breast Carcinoma

Keywords

  • RECIST: Response Evaluation Criteria in Solid Tumors
  • OC: Ovarian Cancer
  • GCIG: Gynecologic Cancer Intergroup
  • Breast carcinoma (Phase 1)
  • Drug therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each participant must meet all of the following inclusion criteria to be enrolled in the study:

  • Female participants 18 years or older
  • Previously treated, or locally recurrent with 1 of the following diagnoses, which has been confirmed histologically or cytologically: adenocarcinoma of the breast (Phase 1 only), recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (Phase 1 and 2)
  • In the Phase 1 portion of the study, participants with breast cancer must have received treatment with at least 1 but no more than 4 prior chemotherapy regimens not including regimens received in the and/or adjuvant setting
  • Participants with breast cancer must have per (RECIST) 1.1
  • No antineoplastic therapy or radiotherapy within 3 weeks before enrollment (2 weeks for regimens with recovery expected within 7 to 14 days) and recovered from toxicities of prior therapy (except alopecia); the participant must have recovered from all treatment-related toxicities and must have evidence of progressive disease (PD) or persistent disease
  • (ECOG) performance status 0 or 1
  • Adequate bone marrow, liver and renal function
  • at least 1 year, OR Surgically sterile, OR If , agree to 2 effective methods of nonhormonal , or agree to completely abstain from heterosexual intercourse
  • Able to provide written
  • Willing to comply with scheduled visits, treatment plan, laboratory tests and other trial procedures
  • Suitable venous access

Specific Inclusion Criteria for participants with Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer:

  • Prior treatments must have included a platinum and a taxane; the most recent treatment need not be a platinum-containing or taxane-containing regimen
  • Disease must have recurred ≤ 12 months after discontinuation of platinum therapy
  • Participants who previously received weekly taxane are potentially eligible, provided that they did not progress during therapy or within 3 months of completing therapy
  • Participants with platinum- disease, as defined by progression during primary or subsequent platinum-based therapy or persistent radiographic disease after primary or subsequent platinum-based therapy, will be included
  • Participants must have measurable disease in target lesions or assessable disease (defined by cancer antigen-125 - CA-125 per protocol), and disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or modified Gynecologic Cancer Intergroup (GCIG) CA-125 criteria

Exclusion criteria

Exclusion Criteria:

Participants meeting any of the following exclusion criteria are not to be enrolled in the study:

  • Prior treatment with an Aurora A-targeted agent (including MLN8237)
  • Treatment with enzyme inducers within 14 days prior to the first dose of MLN8237 and during the study
  • Treatment with more than 4 cytotoxic chemotherapy regimens in the setting; prior therapy cannot include more than 2 prior taxane-containing regimen. Current use of tamoxifen, thalidomide, or any agent used as maintenance or consolidation therapy for OC.
  • Known to Cremophor® EL, paclitaxel or its components
  • Prior history of ≥ Grade 2 neurotoxicity or any toxicity requiring discontinuation from taxane chemotherapy that is not resolved to ≤ Grade 1
  • Comorbid or unresolved toxicity that would preclude administration of weekly paclitaxel
  • Primary central nervous system or carcinomatous meningitis
  • Symptomatic
  • Inability to swallow oral medications or maintain a fast
  • History of hemorrhagic or thrombotic cerebrovascular event in past 12 months
  • Surgery within 3 weeks before study enrollment and not fully recovered
  • Diagnosis or treatment of another malignancy within 2 years preceding first dose of MLN8237 and have any evidence of residual disease except nonmelanoma skin cancer or in situ malignancy completely resected
  • Pregnant or lactating
  • Serious illness that could interfere with protocol completion
  • treatment 21 days prior to first dose of MLN8237
  • Prior allogeneic bone marrow or organ transplantation
  • Infection requiring systemic antibiotic therapy within 14 days prior to first dose of MLN8237
  • Known history of (HIV) infection, , or
  • Radiotherapy to > 25% bone marrow or whole pelvic radiotherapy
  • Requirement for constant administration of proton pump inhibitor, H2 antagonist, or pancreatic enzymes. Intermittent uses of antacids of H2 antagonists are allowed
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
191 participants (actual)

Study arms

  • Experimental
    Alisertib (Phase 1 - Ovarian cancer)

    Participants with ovarian cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg, orally, twice daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or 80 mg/m\^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 1 (Up to 37 cycles).

    Drug: Alisertib · Drug: Paclitaxel

  • Experimental
    Alisertib (Phase 1 - Breast cancer)

    Participants with breast cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg, orally, twice daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or 80 mg/m\^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 1 (Up to 37 cycles).

    Drug: Alisertib · Drug: Paclitaxel

  • Experimental
    Alisertib 40 mg BID+Paclitaxel 60 mg/m^2 (Phase 2)

    Alisertib 40 mg, orally, BID on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 mg/m\^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 2 (Up to 28 cycles).

    Drug: Alisertib · Drug: Paclitaxel

  • Experimental
    Paclitaxel 80 mg/m^2 (Phase 2)

    Paclitaxel 80 mg/m\^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 2 (Up to 28 cycles).

    Drug: Paclitaxel

Interventions

  • Alisertib tablets

    Also known as: MLN8237

  • Paclitaxel intravenous infusion

06

What researchers measure

Primary outcomes

  1. Phase 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel

    The MTD is defined as the dose range at which ≤ 1 of 6 evaluable participants experience dose limiting toxicities (DLT). DLT was evaluated according to National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.02 and was defined as any of the following events: 1. Grade 4 neutropenia and thrombocytopenia lasting ≥7 consecutive days; 2. Grade 4 neutropenia with fever and/or infection; 3. Platelet count \<10,000/mm\^3; 4. Grade 3 thrombocytopenia with bleeding; 5. Any other ≥Grade 3 nonhematologic toxicity, with following exceptions: ≥Grade 3 nausea/emesis, ≥Grade 3 diarrhoea, Grade 3 fatigue, Grade 3 nonhematological toxicity that could be controlled to ≤Grade 2 with appropriate treatment; 6. Other alisertib-related nonhematologic toxicities ≥Grade 2 that, in opinion of investigator, required a dose reduction or discontinuation of therapy with alisertib.

    Time frame: Cycle 1 (Up to 28 days)

  2. Phase 1: MTD and RP2D for Paclitaxel in Combination With Alisertib

    The RP2D is the maximum tolerated dose (MTD) or less. The MTD is defined as the dose range at which ≤ 1 of 6 evaluable participants experience dose limiting toxicities (DLT) within the first 28 days of treatment (end of cycle 1).

    Time frame: Cycle 1 (Up to 28 days)

  3. Phase 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

    Time frame: First dose to 30 days past last dose (Up to 36 Months)

  4. Phase 1: Number of Participants With Clinically Significant Laboratory Values

    Abnormal clinical laboratory values (serum chemistry, hematology and urinalysis) were reported as AEs if they were considered by the investigator to be a clinically significant change from Baseline or led to premature discontinuation of study treatment, dose modification, or other therapeutic intervention.

    Time frame: First dose to 30 days past last dose (Up to 36 Months)

  5. Phase 1: Number of Participants With Clinically Significant Vital Sign Findings

    Vital signs (blood pressure, pulse rate, and oral temperature) measurements were collected throughout the study.

    Time frame: First dose to 30 days past last dose (Up to 36 Months)

  6. Phase 1: Number of Participants With Hypersensitivity and Neurotoxicity

    Time frame: Baseline up to Month 36

  7. Phase 2: Progression-Free Survival (PFS)

    PFS is defined as the time from the date randomization for Phase 2 participants to the date of first documented progressive disease (PD) or death as assessed by the investigator using both RECIST 1.1 criteria and CA-125 criteria. PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease or CA-125 criteria with elevated (\>70 units/mL) levels on 2 occasions. CA 125 progression for participants with normal CA 125 levels is defined as a CA 125 level \> 2 times the upper limit of normal and for participants with elevated values during the trial, is defined as a CA 125 level greater than 2 times the nadir value of CA 125.

    Time frame: At the end of Cycle 2 and at the completion of every 2 cycles until PD was documented or up to data cut-off: 12 August 2014 (approximately 24 months)

Secondary outcomes

  1. Phase 1: Combined Best Overall Response Rate (ORR) in Participants With Recurrent Ovarian Cancer or Breast Cancer

    Combined objective response rate is defined as the percentage of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 or response by Cancer antigen (CA) 125 criteria. According to RECIST: CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter of target lesions. CA 125 response criteria is defined as either: A 50% decrease from 2 initially elevated samples; the sample demonstrating the 50% decrease must have been confirmed by a fourth sample 28 days later (a total of 4 samples required) or A serial decrease of \> 75% over 3 samples; the third sample was to be obtained 28 days after the second (a total of 3 samples required).

    Time frame: At the end of Cycle 2 and at the completion of every 2 cycles until PD was documented or up to data cut-off: 12 August 2014 (approximately 24 months)

  2. Cmax: Maximum Observed Concentration for Alisertib in Phase 1

    Time frame: Days 1 and 3 in Cycle 1: pre-dose and at multiple timepoints (up to 12 hours) post morning dose

  3. Tmax: Time to First Occurrence of Cmax for Alisertib in Phase 1

    Time frame: Days 1 and 3 in Cycle 1: pre-dose and at multiple timepoints (up to 12 hours) post morning dose

  4. AUC(Tau): Area Under the Concentration-Time Curve During a Dosing Interval for Alisertib in Phase 1

    Time frame: Days 1 and 3 in Cycle 1: pre-dose and at multiple timepoints (up to 12 hours) post morning dose

  5. AUClast: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib in Phase 1

    Time frame: Days 1 and 3 in Cycle 1: pre-dose and at multiple timepoints (up to 12 hours) post morning dose

  6. Cmax: Maximum Observed Concentration for Paclitaxel in Phase 1

    Time frame: Day 1 in Cycles 1 and 2: pre-infusion and at multiple timepoints (up to 47 hours) post-infusion

  7. AUClast: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Paclitaxel in Phase 1

    Time frame: Day 1 in Cycles 1 and 2: pre-infusion and at multiple timepoints (up to 47 hours) post-infusion

  8. AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for Paclitaxel in Phase 1

    Time frame: Day 1 in Cycles 1 and 2: pre-infusion and at multiple timepoints (up to 47 hours) post-infusion

  9. t½: Terminal Half-Life for Paclitaxel in Phase 1

    Time frame: Day 1 in Cycles 1 and 2: pre-infusion and at multiple timepoints (up to 47 hours) post-infusion

  10. CL: Total Clearance After Intravenous Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration for Paclitaxel in Phase 1

    Time frame: Day 1 in Cycles 1 and 2: pre-infusion and at multiple timepoints (up to 47 hours) post-infusion

  11. Vss: Volume of Distribution at Steady State for Paclitaxel in Phase 1

    Time frame: Day 1 in Cycles 1 and 2: pre-infusion and at multiple timepoints (up to 47 hours) post-infusion

  12. Vz: Volume of Distribution During the Terminal Disposition Phase for Paclitaxel in Phase 1

    Time frame: Day 1 in Cycles 1 and 2: pre-infusion and at multiple timepoints (up to 47 hours) post-infusion

  13. Phase 2: Combined Best Overall Response Rate (ORR)

    Combined objective response rate is defined as the percentage of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 or response by Cancer antigen (CA) 125 criteria. According to RECIST: CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter of target lesions. CA 125 response criteria is defined as either: A 50% decrease from 2 initially elevated samples; the sample demonstrating the 50% decrease must have been confirmed by a fourth sample 28 days later (a total of 4 samples required) or A serial decrease of \> 75% over 3 samples; the third sample was to be obtained 28 days after the second (a total of 3 samples required).

    Time frame: At the end of Cycle 2 and at the completion of every 2 cycles until PD was documented or up to data cut-off: 12 August 2014 (approximately 24 months)

  14. Phase 2: Duration of Response (DOR)

    DOR was defined as the time from the date of first documentation of a response to the date of first documentation of PD or the last response assessment that is stable disease (SD) or better for a participant who started alternate therapy without progression. PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease or per CA-125 criteria with elevated (\>70 units/mL) levels on 2 occasions. CA 125 progression for participants with normal CA 125 levels is defined as a CA 125 level \> 2 times the upper limit of normal and for participants with elevated values during the trial, is defined as a CA 125 level greater than 2 times the nadir value of CA 125. A responder that did not experience disease progression is censored at the last response assessment that is SD.

    Time frame: Up to data-cut off: 12 August 2014 (approximately 24 months)

  15. Phase 2: Time to Disease Progression (TTP)

    TTP was defined as the time from the date of randomization to the date of first documentation of PD. PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease or per CA-125 criteria with elevated (\>70 units/mL) levels on 2 occasions. CA 125 progression for participants with normal CA 125 levels is defined as a CA 125 level \> 2 times the upper limit of normal and for participants with elevated values during the trial, is defined as a CA 125 level greater than 2 times the nadir value of CA 125.

    Time frame: Up to data-cut off: 12 August 2014 (approximately 24 months)

  16. Phase 2: Overall Survival (OS)

    OS was defined as the time form the date of the randomization to the date of death.

    Time frame: Up to data-cut off: 12 August 2014 (approximately 24 months)

  17. Phase 2: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

    Time frame: First dose to 30 days past last dose (Up to 27 Months)

  18. Phase 2: Number of Participants With Clinically Significant Laboratory Values

    Abnormal clinical laboratory values (serum chemistry, hematology and urinalysis) were reported as AEs if they were considered by the investigator to be a clinically significant change from Baseline or led to premature discontinuation of study treatment, dose modification, or other therapeutic intervention.

    Time frame: First dose to 30 days past last dose (Up to 27 Months)

  19. Phase 2: Number of Participants With Clinically Significant Vital Sign Findings

    Vital signs (blood pressure, pulse rate, and oral temperature) measurements were collected throughout the study.

    Time frame: First dose to 30 days past last dose (Up to 27 Months)

Other outcomes

  1. Banked Tumor Specimens for Candidate Markers of Response to Alisertib and Taxanes

    Time frame: Up to 24 Months

07

Results

Posted Jun 4, 2018

Participant flow

Participants took part in the study at 33 investigative sites in France, Poland and the United States from 16 April 2010 to 19 July 2017. Data cutoff for the primary analysis was 12 August 2014.

Phase 1
Participant flow — Phase 1
MilestoneAlisertib (Phase 1 - Ovarian Cancer)Alisertib (Phase 1 - Breast Cancer)Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2)Paclitaxel 80 mg/m^2 (Phase 2)
Started381100
Completed0000
Not completed381100
Withdrew: Progressive disease24800
Withdrew: Symptomatic deterioration3200
Withdrew: Adverse event2000
Withdrew: Withdrawal by subject7000
Withdrew: Reason not specified0100
Withdrew: Single-patient ind2000
Phase 2
Participant flow — Phase 2
MilestoneAlisertib (Phase 1 - Ovarian Cancer)Alisertib (Phase 1 - Breast Cancer)Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2)Paclitaxel 80 mg/m^2 (Phase 2)
Started007369
Completed0000
Not completed007369
Withdrew: Progressive disease004446
Withdrew: Symptomatic deterioration0016
Withdrew: Adverse event00125
Withdrew: Withdrawal by subject0098
Withdrew: Unsatisfactory therapeutic response0011
Withdrew: Reason not specified0043
Withdrew: Physician decision0020

Outcome measures

PrimaryPhase 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel

The MTD is defined as the dose range at which ≤ 1 of 6 evaluable participants experience dose limiting toxicities (DLT). DLT was evaluated according to National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.02 and was defined as any of the following events: 1. Grade 4 neutropenia and thrombocytopenia lasting ≥7 consecutive days; 2. Grade 4 neutropenia with fever and/or infection; 3. Platelet count \<10,000/mm\^3; 4. Grade 3 thrombocytopenia with bleeding; 5. Any other ≥Grade 3 nonhematologic toxicity, with following exceptions: ≥Grade 3 nausea/emesis, ≥Grade 3 diarrhoea, Grade 3 fatigue, Grade 3 nonhematological toxicity that could be controlled to ≤Grade 2 with appropriate treatment; 6. Other alisertib-related nonhematologic toxicities ≥Grade 2 that, in opinion of investigator, required a dose reduction or discontinuation of therapy with alisertib.

Time frame:
Cycle 1 (Up to 28 days)
Reported as:
Number · mg
Phase 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel
mgAlisertib + Paclitaxel (Phase 1)
Phase 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel40
PrimaryPhase 1: MTD and RP2D for Paclitaxel in Combination With Alisertib

The RP2D is the maximum tolerated dose (MTD) or less. The MTD is defined as the dose range at which ≤ 1 of 6 evaluable participants experience dose limiting toxicities (DLT) within the first 28 days of treatment (end of cycle 1).

Time frame:
Cycle 1 (Up to 28 days)
Reported as:
Number · mg/m^2
Phase 1: MTD and RP2D for Paclitaxel in Combination With Alisertib
mg/m^2Alisertib + Paclitaxel
Phase 1: MTD and RP2D for Paclitaxel in Combination With Alisertib60
PrimaryPhase 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

Time frame:
First dose to 30 days past last dose (Up to 36 Months)
Reported as:
Number · participants
Phase 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsAlisertib (Phase 1 - Ovarian Cancer)Alisertib (Phase 1 - Breast Cancer)
AEs3811
SAEs132
PrimaryPhase 1: Number of Participants With Clinically Significant Laboratory Values

Abnormal clinical laboratory values (serum chemistry, hematology and urinalysis) were reported as AEs if they were considered by the investigator to be a clinically significant change from Baseline or led to premature discontinuation of study treatment, dose modification, or other therapeutic intervention.

Time frame:
First dose to 30 days past last dose (Up to 36 Months)
Reported as:
Number · participants
Phase 1: Number of Participants With Clinically Significant Laboratory Values
participantsAlisertib (Phase 1 - Ovarian Cancer)Alisertib (Phase 1 - Breast Cancer)
Neutrophil count decreased30
White blood cell count decreased11
Aspartate aminotransferase increased31
Alanine aminotransferase increased20
Ammonia increased10
Transaminases increased10
Blood alkaline phosphatase increased11
High density lipoprotein decreased10
Urine output decreased10
Granulocyte count decreased01
PrimaryPhase 1: Number of Participants With Clinically Significant Vital Sign Findings

Vital signs (blood pressure, pulse rate, and oral temperature) measurements were collected throughout the study.

Time frame:
First dose to 30 days past last dose (Up to 36 Months)
Reported as:
Number · participants
Phase 1: Number of Participants With Clinically Significant Vital Sign Findings
participantsAlisertib (Phase 1 - Ovarian Cancer)Alisertib (Phase 1 - Breast Cancer)
Pyrexia85
Heart rate irregular10
Blood pressure increased01
Weight decreased30
PrimaryPhase 1: Number of Participants With Hypersensitivity and Neurotoxicity
Time frame:
Baseline up to Month 36
Reported as:
Number · participants
Phase 1: Number of Participants With Hypersensitivity and Neurotoxicity
participantsAlisertib (Phase 1 - Ovarian Cancer)Alisertib (Phase 1 - Breast Cancer)
Hypersensitivity10
Neurotoxicity00
PrimaryPhase 2: Progression-Free Survival (PFS)

PFS is defined as the time from the date randomization for Phase 2 participants to the date of first documented progressive disease (PD) or death as assessed by the investigator using both RECIST 1.1 criteria and CA-125 criteria. PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease or CA-125 criteria with elevated (\>70 units/mL) levels on 2 occasions. CA 125 progression for participants with normal CA 125 levels is defined as a CA 125 level \> 2 times the upper limit of normal and for participants with elevated values during the trial, is defined as a CA 125 level greater than 2 times the nadir value of CA 125.

Time frame:
At the end of Cycle 2 and at the completion of every 2 cycles until PD was documented or up to data cut-off: 12 August 2014 (approximately 24 months)
Reported as:
Median · days
Phase 2: Progression-Free Survival (PFS)
daysAlisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2)Paclitaxel 80 mg/m^2 (Phase 2)
Phase 2: Progression-Free Survival (PFS)204 (175 to 230)142 (117 to 148)
SecondaryPhase 1: Combined Best Overall Response Rate (ORR) in Participants With Recurrent Ovarian Cancer or Breast Cancer

Combined objective response rate is defined as the percentage of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 or response by Cancer antigen (CA) 125 criteria. According to RECIST: CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter of target lesions. CA 125 response criteria is defined as either: A 50% decrease from 2 initially elevated samples; the sample demonstrating the 50% decrease must have been confirmed by a fourth sample 28 days later (a total of 4 samples required) or A serial decrease of \> 75% over 3 samples; the third sample was to be obtained 28 days after the second (a total of 3 samples required).

Time frame:
At the end of Cycle 2 and at the completion of every 2 cycles until PD was documented or up to data cut-off: 12 August 2014 (approximately 24 months)
Reported as:
Number · percentage of participants
Phase 1: Combined Best Overall Response Rate (ORR) in Participants With Recurrent Ovarian Cancer or Breast Cancer
percentage of participantsAlisertib (Phase 1 - Ovarian Cancer)Alisertib (Phase 1 - Breast Cancer)
Phase 1: Combined Best Overall Response Rate (ORR) in Participants With Recurrent Ovarian Cancer or Breast Cancer47 (36 to 59)55 (32 to 76)
SecondaryCmax: Maximum Observed Concentration for Alisertib in Phase 1
Time frame:
Days 1 and 3 in Cycle 1: pre-dose and at multiple timepoints (up to 12 hours) post morning dose
Reported as:
Mean · ng/mL
Cmax: Maximum Observed Concentration for Alisertib in Phase 1
ng/mLAlisertib 10 mg BID + Paclitaxel 80 mg/m^2Alisertib 20 mg BID + Paclitaxel 80 mg/m^2Alisertib 20 mg BID + Paclitaxel 60 mg/m^2Alisertib 30 mg BID + Paclitaxel 60 mg/m^2Alisertib 40 mg BID + Paclitaxel 60 mg/m^2Alisertib 50 mg BID + Paclitaxel 60 mg/m^2
Cycle1 (Day1)428.7 ± 189.59766.8 ± 312.10900.00 ± 392.171365.3 ± 466.511398.7 ± 607.701960.0 ± 515.65
Cycle1 (Day3)594.3 ± 228.461042.3 ± 280.95871.3 ± 268.231708.5 ± 820.542493.4 ± 955.314456.7 ± 947.33
SecondaryTmax: Time to First Occurrence of Cmax for Alisertib in Phase 1
Time frame:
Days 1 and 3 in Cycle 1: pre-dose and at multiple timepoints (up to 12 hours) post morning dose
Reported as:
Median · hour
Tmax: Time to First Occurrence of Cmax for Alisertib in Phase 1
hourAlisertib 10 mg BID + Paclitaxel 80 mg/m^2Alisertib 20 mg BID + Paclitaxel 80 mg/m^2Alisertib 20 mg BID + Paclitaxel 60 mg/m^2Alisertib 30 mg BID + Paclitaxel 60 mg/m^2Alisertib 40 mg BID + Paclitaxel 60 mg/m^2Alisertib 50 mg BID + Paclitaxel 60 mg/m^2
Cycle 1, Day 13.0 ± 189.593.1 ± 312.102.6 ± 392.172.5 ± 466.513.0 ± 607.702.0 ± 515.65
Cycle 1, Day 32.2 ± 228.463.0 ± 280.953.5 ± 268.232.0 ± 820.542.0 ± 955.312.0 ± 947.33
SecondaryAUC(Tau): Area Under the Concentration-Time Curve During a Dosing Interval for Alisertib in Phase 1
Time frame:
Days 1 and 3 in Cycle 1: pre-dose and at multiple timepoints (up to 12 hours) post morning dose
Reported as:
Mean · ng/mL*hour(hr)
AUC(Tau): Area Under the Concentration-Time Curve During a Dosing Interval for Alisertib in Phase 1
ng/mL*hour(hr)Alisertib 10 mg BID + Paclitaxel 80 mg/m^2Alisertib 20 mg BID + Paclitaxel 80 mg/m^2Alisertib 20 mg BID + Paclitaxel 60 mg/m^2Alisertib 30 mg BID + Paclitaxel 60 mg/m^2Alisertib 40 mg BID + Paclitaxel 60 mg/m^2Alisertib 50 mg BID + Paclitaxel 60 mg/m^2
Cycle 1, Day 12519.3 ± 937.525175.0 ± 1766.115610.0 ± 2105.428581.7 ± 3225.649594.0 ± 4600.4214666.7 ± 3707.20
Cycle 1, Day33966.7 ± 1112.117745.0 ± 2233.916155.0 ± 1737.6912478.3 ± 6013.9317557.3 ± 7856.3035500.0 ± 12842.12
SecondaryAUClast: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib in Phase 1
Time frame:
Days 1 and 3 in Cycle 1: pre-dose and at multiple timepoints (up to 12 hours) post morning dose
Reported as:
Mean · ng/mL*hr
AUClast: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib in Phase 1
ng/mL*hrAlisertib 10 mg BID + Paclitaxel 80 mg/m^2Alisertib 20 mg BID + Paclitaxel 80 mg/m^2Alisertib 20 mg BID + Paclitaxel 60 mg/m^2Alisertib 30 mg BID + Paclitaxel 60 mg/m^2Alisertib 40 mg BID + Paclitaxel 60 mg/m^2Alisertib 50 mg BID + Paclitaxel 60 mg/m^2
Cycle 1, Day 12519.3 ± 937.525175.0 ± 1766.115610.0 ± 2105.428581.7 ± 3225.649594.0 ± 4600.4214666.7 ± 3707.20
Cycle 1, Day 33966.7 ± 1112.117745.0 ± 2233.916155.0 ± 1737.6912478.3 ± 6013.9317557.3 ± 7856.3035500.0 ± 12842.12
SecondaryCmax: Maximum Observed Concentration for Paclitaxel in Phase 1
Time frame:
Day 1 in Cycles 1 and 2: pre-infusion and at multiple timepoints (up to 47 hours) post-infusion
Reported as:
Mean · ng/mL
Cmax: Maximum Observed Concentration for Paclitaxel in Phase 1
ng/mLAlisertib 10 mg BID + Paclitaxel 80 mg/m^2Alisertib 20 mg BID + Paclitaxel 80 mg/m^2Alisertib 20 mg BID + Paclitaxel 60 mg/m^2Alisertib 30 mg BID + Paclitaxel 60 mg/m^2Alisertib 40 mg BID + Paclitaxel 60 mg/m^2Alisertib 50 mg BID + Paclitaxel 60 mg/m^2
Cycle 1, Day 13097.3 ± 1114.513120.0 ± 447.752117.5 ± 745.542448.0 ± 988.651917.3 ± 528.321338.7 ± 617.94
Cycle 2, Day 12654.6 ± 696.453231.7 ± 615.641733.3 ± 541.972478.3 ± 878.391492.7 ± 558.141750.0 ± 183.85
SecondaryAUClast: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Paclitaxel in Phase 1
Time frame:
Day 1 in Cycles 1 and 2: pre-infusion and at multiple timepoints (up to 47 hours) post-infusion
Reported as:
Mean · ng/mL*hr
AUClast: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Paclitaxel in Phase 1
ng/mL*hrAlisertib 10 mg BID + Paclitaxel 80 mg/m^2Alisertib 20 mg BID + Paclitaxel 80 mg/m^2Alisertib 20 mg BID + Paclitaxel 60 mg/m^2Alisertib 30 mg BID + Paclitaxel 60 mg/m^2Alisertib 40 mg BID + Paclitaxel 60 mg/m^2Alisertib 50 mg BID + Paclitaxel 60 mg/m^2
Cycle 1, Day 14437.7 ± 1053.874825.0 ± 735.173355.0 ± 865.893366.0 ± 1139.252652.7 ± 651.322190.0 ± 387.43
Cycle 2, Day 14061.7 ± 1298.865301.7 ± 1183.312660.0 ± 307.903056.0 ± 812.672231.5 ± 604.762460.0 ± 14.14
SecondaryAUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for Paclitaxel in Phase 1
Time frame:
Day 1 in Cycles 1 and 2: pre-infusion and at multiple timepoints (up to 47 hours) post-infusion
Reported as:
Mean · ng/mL*hr
AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for Paclitaxel in Phase 1
ng/mL*hrAlisertib 10 mg BID + Paclitaxel 80 mg/m^2Alisertib 20 mg BID + Paclitaxel 80 mg/m^2Alisertib 20 mg BID + Paclitaxel 60 mg/m^2Alisertib 30 mg BID + Paclitaxel 60 mg/m^2Alisertib 40 mg BID + Paclitaxel 60 mg/m^2Alisertib 50 mg BID + Paclitaxel 60 mg/m^2
Cycle 1, Day 15317.8 ± 1052.405238.0 ± 812.263860.0 ± 824.203375.0 ± 1130.563175.5 ± 933.102535.0 ± 657.61
Cycle 2, Day 14606.4 ± 1391.355584.0 ± 1367.513185.0 ± 176.783415.0 ± 1010.822680.0 ± 607.22—
Secondaryt½: Terminal Half-Life for Paclitaxel in Phase 1
Time frame:
Day 1 in Cycles 1 and 2: pre-infusion and at multiple timepoints (up to 47 hours) post-infusion
Reported as:
Mean · hour
t½: Terminal Half-Life for Paclitaxel in Phase 1
hourAlisertib 10 mg BID + Paclitaxel 80 mg/m^2Alisertib 20 mg BID + Paclitaxel 80 mg/m^2Alisertib 20 mg BID + Paclitaxel 60 mg/m^2Alisertib 30 mg BID + Paclitaxel 60 mg/m^2Alisertib 40 mg BID + Paclitaxel 60 mg/m^2Alisertib 50 mg BID + Paclitaxel 60 mg/m^2
Cycle 1, Day 117.2 ± 4.2017.5 ± 1.8717.3 ± 4.1613.9 ± 4.6816.8 ± 6.8318.4 ± 8.70
Cycle 2, Day 117.0 ± 3.6316.2 ± 5.0517.3 ± 5.2316.5 ± 4.3213.3 ± 5.5914.6 ± 2.19
SecondaryCL: Total Clearance After Intravenous Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration for Paclitaxel in Phase 1
Time frame:
Day 1 in Cycles 1 and 2: pre-infusion and at multiple timepoints (up to 47 hours) post-infusion
Reported as:
Mean · liter per hour
CL: Total Clearance After Intravenous Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration for Paclitaxel in Phase 1
liter per hourAlisertib 10 mg BID + Paclitaxel 80 mg/m^2Alisertib 20 mg BID + Paclitaxel 80 mg/m^2Alisertib 20 mg BID + Paclitaxel 60 mg/m^2Alisertib 30 mg BID + Paclitaxel 60 mg/m^2Alisertib 40 mg BID + Paclitaxel 60 mg/m^2Alisertib 50 mg BID + Paclitaxel 60 mg/m^2
Cycle 1, Day 129.756 ± 6.817528.220 ± 5.180426.800 ± 7.538640.950 ± 17.526838.055 ± 13.709538.950 ± 11.2430
Cycle 2, Day 135.827 ± 10.400528.240 ± 7.374833.900 ± 5.232634.250 ± 8.261442.440 ± 10.4296—
SecondaryVss: Volume of Distribution at Steady State for Paclitaxel in Phase 1
Time frame:
Day 1 in Cycles 1 and 2: pre-infusion and at multiple timepoints (up to 47 hours) post-infusion
Reported as:
Mean · liter
Vss: Volume of Distribution at Steady State for Paclitaxel in Phase 1
literAlisertib 10 mg BID + Paclitaxel 80 mg/m^2Alisertib 20 mg BID + Paclitaxel 80 mg/m^2Alisertib 20 mg BID + Paclitaxel 60 mg/m^2Alisertib 30 mg BID + Paclitaxel 60 mg/m^2Alisertib 40 mg BID + Paclitaxel 60 mg/m^2Alisertib 50 mg BID + Paclitaxel 60 mg/m^2
Cycle 1, Day 1313.444 ± 118.6593310.800 ± 86.9235330.000 ± 208.8851357.000 ± 158.1834433.909 ± 179.7757460.500 ± 103.9447
Cycle 2, Day 1391.364 ± 64.3137283.200 ± 121.1123413.500 ± 242.5376377.000 ± 118.9650372.600 ± 180.7332—
SecondaryVz: Volume of Distribution During the Terminal Disposition Phase for Paclitaxel in Phase 1
Time frame:
Day 1 in Cycles 1 and 2: pre-infusion and at multiple timepoints (up to 47 hours) post-infusion
Reported as:
Mean · liter
Vz: Volume of Distribution During the Terminal Disposition Phase for Paclitaxel in Phase 1
literAlisertib 10 mg BID + Paclitaxel 80 mg/m^2Alisertib 20 mg BID + Paclitaxel 80 mg/m^2Alisertib 20 mg BID + Paclitaxel 60 mg/m^2Alisertib 30 mg BID + Paclitaxel 60 mg/m^2Alisertib 40 mg BID + Paclitaxel 60 mg/m^2Alisertib 50 mg BID + Paclitaxel 60 mg/m^2
Cycle 1, Day 1705.000 ± 179.0223721.600 ± 203.8021694.000 ± 352.1534850.500 ± 291.0401872.727 ± 328.6202956.500 ± 188.7975
Cycle 2, Day 1829.364 ± 156.6060663.200 ± 321.3070865.500 ± 388.2016777.250 ± 103.7027733.000 ± 208.4898—
SecondaryPhase 2: Combined Best Overall Response Rate (ORR)

Combined objective response rate is defined as the percentage of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 or response by Cancer antigen (CA) 125 criteria. According to RECIST: CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter of target lesions. CA 125 response criteria is defined as either: A 50% decrease from 2 initially elevated samples; the sample demonstrating the 50% decrease must have been confirmed by a fourth sample 28 days later (a total of 4 samples required) or A serial decrease of \> 75% over 3 samples; the third sample was to be obtained 28 days after the second (a total of 3 samples required).

Time frame:
At the end of Cycle 2 and at the completion of every 2 cycles until PD was documented or up to data cut-off: 12 August 2014 (approximately 24 months)
Reported as:
Number · percentage of participants
Phase 2: Combined Best Overall Response Rate (ORR)
percentage of participantsAlisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2)Paclitaxel 80 mg/m^2 (Phase 2)
Phase 2: Combined Best Overall Response Rate (ORR)60 (51 to 68)52 (43 to 60)
SecondaryPhase 2: Duration of Response (DOR)

DOR was defined as the time from the date of first documentation of a response to the date of first documentation of PD or the last response assessment that is stable disease (SD) or better for a participant who started alternate therapy without progression. PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease or per CA-125 criteria with elevated (\>70 units/mL) levels on 2 occasions. CA 125 progression for participants with normal CA 125 levels is defined as a CA 125 level \> 2 times the upper limit of normal and for participants with elevated values during the trial, is defined as a CA 125 level greater than 2 times the nadir value of CA 125. A responder that did not experience disease progression is censored at the last response assessment that is SD.

Time frame:
Up to data-cut off: 12 August 2014 (approximately 24 months)
Reported as:
Median · days
Phase 2: Duration of Response (DOR)
daysAlisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2)Paclitaxel 80 mg/m^2 (Phase 2)
Phase 2: Duration of Response (DOR)201 (181 to 218)169 (120 to 231)
SecondaryPhase 2: Time to Disease Progression (TTP)

TTP was defined as the time from the date of randomization to the date of first documentation of PD. PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease or per CA-125 criteria with elevated (\>70 units/mL) levels on 2 occasions. CA 125 progression for participants with normal CA 125 levels is defined as a CA 125 level \> 2 times the upper limit of normal and for participants with elevated values during the trial, is defined as a CA 125 level greater than 2 times the nadir value of CA 125.

Time frame:
Up to data-cut off: 12 August 2014 (approximately 24 months)
Reported as:
Median · days
Phase 2: Time to Disease Progression (TTP)
daysAlisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2)Paclitaxel 80 mg/m^2 (Phase 2)
Phase 2: Time to Disease Progression (TTP)204 (175 to 232)142 (117 to 161)
SecondaryPhase 2: Overall Survival (OS)

OS was defined as the time form the date of the randomization to the date of death.

Time frame:
Up to data-cut off: 12 August 2014 (approximately 24 months)
Reported as:
Median · days
Phase 2: Overall Survival (OS)
daysAlisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2)Paclitaxel 80 mg/m^2 (Phase 2)
Phase 2: Overall Survival (OS)NA (NA to NA)NA (NA to NA)
SecondaryPhase 2: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

Time frame:
First dose to 30 days past last dose (Up to 27 Months)
Reported as:
Number · participants
Phase 2: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsAlisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2)Paclitaxel 80 mg/m^2 (Phase 2)
AEs7366
SAEs3019
SecondaryPhase 2: Number of Participants With Clinically Significant Laboratory Values

Abnormal clinical laboratory values (serum chemistry, hematology and urinalysis) were reported as AEs if they were considered by the investigator to be a clinically significant change from Baseline or led to premature discontinuation of study treatment, dose modification, or other therapeutic intervention.

Time frame:
First dose to 30 days past last dose (Up to 27 Months)
Reported as:
Number · participants
Phase 2: Number of Participants With Clinically Significant Laboratory Values
participantsAlisertib 40 mg BID + Paclitaxel 60 mg/m^2 (Phase 2)Paclitaxel 80 mg/m^2 (Phase 2)
Neutrophil count decreased144
White blood cell count decreased61
Lymphocyte count decreased11
Aspartate aminotransferase increased13
Alanine aminotransferase increased14
Gamma-glutamyltransferase increased01
Blood alkaline phosphatase increased22
Haemoglobin decreased31
Blood magnesium decreased03
Blood creatinine increased12
Platelet count decreased20
International normalised ratio increased10
Blood albumin decreased10
Troponin T increased01
SecondaryPhase 2: Number of Participants With Clinically Significant Vital Sign Findings

Vital signs (blood pressure, pulse rate, and oral temperature) measurements were collected throughout the study.

Time frame:
First dose to 30 days past last dose (Up to 27 Months)
Reported as:
Number · participants
Phase 2: Number of Participants With Clinically Significant Vital Sign Findings
participantsAlisertib 40 mg BID + Paclitaxel 60 mg/m^2 (Phase 2)Paclitaxel 80 mg/m^2 (Phase 2)
Pyrexia158
Heart rate increased10
Blood pressure increased10
Weight decreased82
Other pre-specifiedBanked Tumor Specimens for Candidate Markers of Response to Alisertib and Taxanes
Time frame:
Up to 24 Months

No measurements were reported for this outcome.

Adverse events

Collected over Phase 1: First dose to 30 days past last dose (Up to 36 Months); Phase 2: First dose to 30 days past last dose (Up to 27 Months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alisertib (Phase 1 - Ovarian Cancer)—13/38 (34.2%)38/38 (100%)
Alisertib (Phase 1 - Breast Cancer)—2/11 (18.2%)11/11 (100%)
Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2)—30/73 (41.1%)73/73 (100%)
Paclitaxel 80 mg/m^2 (Phase 2)—19/69 (27.5%)64/69 (92.8%)
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventAlisertib (Phase 1 - Ovarian Cancer)Alisertib (Phase 1 - Breast Cancer)Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2)Paclitaxel 80 mg/m^2 (Phase 2)
Febrile neutropeniaBlood and lymphatic system disorders6/380/119/730/69
CellulitisInfections and infestations1/381/110/730/69
SepsisInfections and infestations0/381/111/731/69
PyrexiaGeneral disorders0/381/113/732/69
FatigueGeneral disorders1/381/110/731/69
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/381/112/731/69
HypotensionVascular disorders1/381/110/730/69
NeutropeniaBlood and lymphatic system disorders0/380/116/730/69
Intestinal obstructionGastrointestinal disorders0/380/114/731/69
DehydrationMetabolism and nutrition disorders0/380/114/730/69
Most frequent other events
Showing 10 of 179
Most frequent other events
EventAlisertib (Phase 1 - Ovarian Cancer)Alisertib (Phase 1 - Breast Cancer)Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2)Paclitaxel 80 mg/m^2 (Phase 2)
NeutropeniaBlood and lymphatic system disorders24/3810/1152/7310/69
DiarrhoeaGastrointestinal disorders27/388/1146/7315/69
StomatitisGastrointestinal disorders15/388/1146/736/69
FatigueGeneral disorders26/388/1143/7331/69
LeukopeniaBlood and lymphatic system disorders20/388/1111/733/69
AlopeciaSkin and subcutaneous tissue disorders26/385/1128/7322/69
AnaemiaBlood and lymphatic system disorders22/387/1133/7320/69
NauseaGastrointestinal disorders23/385/1132/7332/69
ConstipationGastrointestinal disorders15/383/1126/7317/69
Oedema peripheralGeneral disorders15/383/1112/7318/69

Baseline characteristics

Safety population was defined as all participants who received at least 1 dose of any study drug.

Age, Continuous
Age, Continuous(years)Alisertib (Phase 1 - Ovarian Cancer)Alisertib (Phase 1 - Breast Cancer)Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2)Paclitaxel 80 mg/m^2 (Phase 2)Total
Mean55.8 ± 10.2958.6 ± 10.0661.0 ± 11.6060.8 ± 8.4159.8 ± 10.32
Sex: Female, Male
Sex: Female, Male(Participants)Alisertib (Phase 1 - Ovarian Cancer)Alisertib (Phase 1 - Breast Cancer)Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2)Paclitaxel 80 mg/m^2 (Phase 2)Total
Female38117369191
Male00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Alisertib (Phase 1 - Ovarian Cancer)Alisertib (Phase 1 - Breast Cancer)Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2)Paclitaxel 80 mg/m^2 (Phase 2)Total
Hispanic or Latino40149
Not Hispanic or Latino34106462170
Not Reported017311
Missing00101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Alisertib (Phase 1 - Ovarian Cancer)Alisertib (Phase 1 - Breast Cancer)Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2)Paclitaxel 80 mg/m^2 (Phase 2)Total
White34116655166
Black or African American302611
Asian10124
American Indian or Alaskan Native00022
Other00112
Not Reported00235
Missing00101
Region of Enrollment
Region of Enrollment(participants)Alisertib (Phase 1 - Ovarian Cancer)Alisertib (Phase 1 - Breast Cancer)Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2)Paclitaxel 80 mg/m^2 (Phase 2)Total
United States38114845142
Poland0010818
France00151631
Height
Height(cm)Alisertib (Phase 1 - Ovarian Cancer)Alisertib (Phase 1 - Breast Cancer)Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2)Paclitaxel 80 mg/m^2 (Phase 2)Total
Mean164.2 ± 6.41164.5 ± 6.38162.4 ± 7.02161.9 ± 7.30162.7 ± 6.99
Weight
Weight(kg)Alisertib (Phase 1 - Ovarian Cancer)Alisertib (Phase 1 - Breast Cancer)Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2)Paclitaxel 80 mg/m^2 (Phase 2)Total
Mean75.86 ± 16.4176.29 ± 7.2970.42 ± 14.7872.50 ± 18.7172.59 ± 16.37
Body Surface Area
Body Surface Area(m^2)Alisertib (Phase 1 - Ovarian Cancer)Alisertib (Phase 1 - Breast Cancer)Alisertib 40 mg BID+ Paclitaxel 60 mg/m^2 (Phase 2)Paclitaxel 80 mg/m^2 (Phase 2)Total
Mean1.850 ± 0.211.865 ± 0.101.776 ± 0.201.794 ± 0.241.802 ± 0.21
08

Study locations

4 sites
  • Bronx, New York, United States
  • Philadelphia, Pennsylvania, United States
  • Houston, Texas, United States
  • Seattle, Washington, United States
09

References and documents

Publications

  • Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2019 Jan 1;5(1):e183773. doi: 10.1001/jamaoncol.2018.3773. Epub 2019 Jan 10. PubMed 30347019 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2010 to primary completion in Aug 2014, 51 months.

Results were first posted in Jun 2018, 3 years 9 months after primary completion. A results delay was requested in Feb 2017.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 51 months is above that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2010
First posted
Mar 24, 2010
StartActual
Apr 16, 2010
Primary completionActual
Aug 12, 2014
CompletionActual
Jul 19, 2017
Results delay requested
Feb 8, 2017
Results first posted
Jun 4, 2018
Last update
Jun 4, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01091428
Responsible party
Sponsor
First posted
Mar 24, 2010
Start date
Apr 16, 2010
Primary completion
Aug 12, 2014
Completion
Jul 19, 2017
Results posted
Jun 4, 2018
Last update
Jun 4, 2018

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paclitaxel

Start the discussion